31 Mar 20
tranScrip is pleased to note that Synairgen has confirmed commencement of first patient dosing in a trial of SNG001 in COVID-19.
tranScrip continues to support Synairgen in this important endeavour, a continuation of being at the heart of the development of SNG001 (inhaled formulation of interferon-beta-1a) for the last 12 years.
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts can support you to maximise the value of your products. Whatever your project requires, we have the expertise to meet your needs.
